Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 211

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study

Open access
Cohen, Roger B., Delord, Jean-Pierre, Doi, Toshihiko, Piha-Paul, Sarina A., Liu, Stephen V., Gilbert, Jill, Algazi, Alain P., Damian, Silvia, Hong, Ruey-Long, Le Tourneau, Christophe, Day, Daphne, Varga, Andrea, Elez, Elena, Wallmark, John, Saraf, Sanatan, Thanigaimani, Pradeep, Cheng, Jonathan, Keam, Bhumsuk · 2018 · American Journal of Clinical Oncology

Abstract

Objectives: Treatment options for patients with unresectable or metastatic salivary gland carcinoma (SGC) are limited. Safety and efficacy of pembrolizumab for SGC expressing programmed death ligand 1 (PD-L1) were explored. Materials and Methods: A cohort of patients with advanced, PD-L1-positive SGC was enrolled in the nonrandomized, multicohort, phase Ib trial of pembrolizumab in patients with PD-L1-positive advanced solid tumors (KEYNOTE-028; NCT02054806). Key inclusion criteria included recurrent or metastatic disease, failure of prior systemic therapy, and PD-L1 expression on ≥1% of tumor or stroma cells (per a prototype immunohistochemistry assay). Patients received pembrolizumab 10 mg/kg every 2 weeks for ≥2 years or until confirmed disease progression or unacceptable toxicity. Primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 by investigator review. Results: Twenty-six patients with PD-L1-positive SGC were enrolled and treated; median age was 57 years, 88% were men, and 74% had received prior therapy for recurrent/metastatic disease. Confirmed objective response rate after median follow-up of 20 months was 12% (95% confidence interval, 2%-30%), with 3 patients achieving partial response; there were no complete responses. Median duration of response was 4 months (range, 4 to 21 mo). Treatment-related adverse events occurred in 22 patients (85%), resulting in discontinuation in 2 patients and death in 1 (interstitial lung disease); those occurring in ≥15% of patients were diarrhea, decreased appetite, pruritus, and fatigue. Conclusions: Pembrolizumab demonstrated promising antitumor activity and a manageable safety profile in patients with advanced, PD-L1-positive SGC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/coc.0000000000000429

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 211

Metadata

Authors
Cohen, R. B., Delord, J.-P., Doi, T., Piha-Paul, S. A., Liu, S. V., Gilbert, J., Algazi, A. P., Damian, S., Hong, R.-L., Le Tourneau, C., Day, D., Varga, A., Elez, E., Wallmark, J., Saraf, S., Thanigaimani, P., Cheng, J., & Keam, B.
Venue
American Journal of Clinical Oncology
Published
2018-11
Volume
41
Issue
11
Pages
1083-1088
ISSN
0277-3732 (ISSN-L)
OpenAlex
W2792603138
Cited by
211
References
2
FWCI
20.03
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. https://app.cochat.ai/papers/10.1097/coc.0000000000000429
The paper
Cohen, R. B., Delord, J.-P., Doi, T., Piha-Paul, S. A., Liu, S. V., Gilbert, J., Algazi, A. P., Damian, S., Hong, R.-L., Le Tourneau, C., Day, D., Varga, A., Elez, E., Wallmark, J., Saraf, S., Thanigaimani, P., Cheng, J., & Keam, B. (2018). Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. American Journal of Clinical Oncology. https://doi.org/10.1097/coc.0000000000000429

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.